Revelation Biosciences, Inc.
REVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,796 | $10,303 | $10,759 | $100,588 |
| - Cash | $6,499 | $11,992 | $5,253 | $1,275 |
| + Debt | $0 | $0 | $0 | $17 |
| Enterprise Value | -$2,704 | -$1,688 | $5,507 | $99,330 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$7,947 | -$8,632 | -$10,839 | -$11,934 |
| % Margin | – | – | – | – |
| Net Income | -$15,039 | -$120 | -$10,830 | -$11,987 |
| % Margin | – | – | – | – |
| EPS Diluted | -87.68 | -8.41 | -9,643.37 | -20,400 |
| % Growth | -942.6% | 99.9% | 52.7% | – |
| Operating Cash Flow | -$18,321 | -$7,286 | -$11,219 | -$11,091 |
| Capital Expenditures | -$19 | $0 | $0 | -$132 |
| Free Cash Flow | -$18,340 | -$7,286 | -$11,219 | -$11,223 |